Nexteras technology offers a highly versatile and innovative platform that finds its application in a broad array of fields leaning on protein engineering and evolution, such as life sciences, IVD, drug discovery and lead optimization. Nexteras strategy is to build on our true uniqueness and core strengths to differentiate from competition and maximize value creation. Thus, the company focuses on high-resolution target discovery and lead candidate development in HLA class II associated mechanisms. For all leads developed by Nextera, a companion diagnostic will also be included given the nature of our applied discovery tools.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a British company located in Cambridge that functions as an holding company whose subsidiaries researches, develops and exploits molecular engineering products. It was founded in 1996.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

COSMIX molecular biologicals is operates as a biotechnology company which is using proprietary technologies to develop highly specific binding peptides for diagnostic, imaging, and bio purifications industries. It is engages in the development of D-peptide drugs and licensing opportunities for high affinity ligands HAL for bioprocessing.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

WELGENE, Inc. develops and manufactures life science reagents. The firm's products include cell culture, molecular biology, and protein related products. The company is headquartered in Gyeongsan, South Korea.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Zumutor Biologics, Inc. engages in developing antibody engineering platforms. It offer novel immunotherapies and regulates tumor microenvironment. The company was founded by Sohang Chatterjee and Kavitha Iyer Rodrigues in 2003 and is headquartered in Cambridge,MA.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Los Alamos National Security LLC is an American private company located in Los Alamos, NM. The firm provides research, development and testing services.

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

Cangene is a fully integrated developer and manufacturer of immune therapeutics. Our first drug, WinRho® SDF, has been commercially available since 1980, and since then we have established a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas. Our current product portfolio consists of purified, concentrated antibody preparations (hyperimmunes) with target applications in infectious disease, hematology, transplantation and biodefense. Four of our hyperimmune products are approved in the United States and/or Canada, and three products are included in the U.S. Strategic National Stockpile. We are committed to the safety and quality of our products, the service of our customers, and the interests of our shareholders.

Biostapro AB provides vaccine research. It develops human monoclonal antibodies against Staphylococcal and bacterial infections. The company is located in Uppsala, Sweden.